Publication | Closed Access

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

MedicineImmunologyPathologyImmune Checkpoint InhibitorNasopharyngeal CarcinomaAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyPhase 1Molecular Oncology